Recent Updates
Recently added Catalysts
MRVI Negative Sentiment Score: 25/100

Maravai LifeSciences Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – MRVI

Key Takeaway: Maravai LifeSciences Holdings, Inc. is currently facing a class action securities lawsuit for alleged violations of securities laws. The lawsuit targets investors who experienced losses from August 7, 2024, to February 24, 2025, due to misleading statements regarding the company's financial reporting and internal controls. Allegations include inaccurate revenue recognition and overstated goodwill. Investors have until May 5, 2025, to participate in the lawsuit. Legal representation is being offered with no out-of-pocket costs.

Market Sentiment Analysis

CONCERNS & RISKS

  • Maravai LifeSciences is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit claims the company had inadequate internal controls over financial reporting.
  • Allegations include inaccurate revenue recognition and overstated goodwill.

Full Press Release Details

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Maravai LifeSciences Holdings, Inc. ("Maravai LifeSciences" or the "Company") (NASDAQ: MRVI) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Maravai LifeSciences investors who were adversely affected by alleged securities fraud between August 7, 2024 and February 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
MRVI investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4)as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Maravai LifeSciences during the relevant time frame, you have until May 5, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the Maravai LifeSciences lawsuit about?

The lawsuit aims to recover losses for investors due to alleged securities fraud.

What are the key allegations in the case?

The case alleges false statements regarding internal controls and revenue recognition.

What is the deadline to join the class action?

Investors can join the class action until May 5, 2025.

Will it cost anything to participate in the lawsuit?

Participation in the lawsuit is free for class members; no fees apply.

Why choose Levi & Korsinsky for this case?

They have a strong track record in securities litigation, securing significant recoveries.

Last updated: Mar 7, 2025